2025-10-17T17:16:00-05:00 2024-12-31 946214841 ARMANINO ADVISORY LLC 1520 S FIFTH STREET SUITE 309 ST CHARLES MO 63303 990 2024-01-01 272233336 PEDAL THE CAUSE PEDA 3147871990 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 DAVID DRIER EXECUTIVE DIRECTOR 3147871990 2025-10-16 1 1 JENNIFER M VACHA P01251998 6362553000 2025-10-16 2024 2025-03-06 01:10:19Z DAVID DRIER 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 9652328 0 X WWW.PEDALTHECAUSE.ORG X 2010 MO TO CONDUCT AN ANNUAL FUNDRAISING BIKE CHALLENGE TO RAISE AWARENESS AND FUNDS FOR CANCER RESEARCH. 29 29 11 700 0 0 6695334 9051296 406030 378584 40528 96012 -39733 -62442 7102159 9463450 5003916 5204913 0 0 927586 1139109 0 0 744981 1370109 1372893 7301611 7716915 -199452 1746535 1476656 3191041 238709 206559 1237947 2984482 X OUR MISSION IS TO PROVIDE FUNDING FOR CANCER RESEARCH AT SITEMAN CANCER CENTER AND SITEMAN KIDS AT ST. LOUIS CHILDREN'S HOSPITAL THROUGH OUR ANNUAL CYCLE CHALLENGE. IT IS OUR HOPE THAT RESEARCH FUNDED BY PEDAL THE CAUSE WILL ULTIMATELY LEAD TO A CURE FOR CANCER. 0 0 6577937 5204913 402491 IN 2024, OVER 3,200 ADULTS AND CHILDREN PARTICIPATED IN PEDAL THE CAUSE, SUPPORTED BY 700 VOLUNTEERS, WHO TOGETHER RAISED OVER $5.2 MILLION TO FUND CANCER RESEARCH. OVER THE PAST 15 YEARS, PEDAL THE CAUSE HAS CUMULATIVELY DONATED $51 MILLION SUPPORTING 255 ADULT AND PEDIATRIC CANCER RESEARCH PROJECTS. MAJOR BREAKTHROUGHS MADE POSSIBLE BY PEDAL THE CAUSE FUNDS INCLUDE THE DEVELOPMENT OF DNA AND PEPTIDE VACCINES FOR MULTIPLE CANCER TYPES, CANCER GOOGLES TO HELP SURGEONS SEE CANCER CELLS, IMMUNOTHERAPY HARNESSING OUR BODY'S 'NATURAL KILLER' CELLS AND CUTTING-EDGE RESEARCH IN THE UNDERSTANDING OF CANCER STEM-CELLS. (CONTINUED ON SCHEDULE O)PEDAL THE CAUSE FUNDS HAVE BEEN INSTRUMENTAL IN OBTAINING SPORE (SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE) GRANTS IN LEUKEMIA AND PANCREATIC CANCER, WHICH LEAD A NATIONAL GROUP OF EXPERTS IN COLLABORATIVE RESEARCH. PEDAL THE CAUSE FUNDED CLINICAL TRIALS ARE A KEY COMPONENT OF THE ROBUST CLINICAL TRIAL PROGRAM AT SITEMAN CANCER CENTER, WHICH RANKS AS THE LARGEST CANCER CLINICAL TRIALS PROGRAM IN THE MIDWEST AND THIRD LARGEST IN THE COUNTRY. FOR EVERY $1 PEDAL THE CAUSE DONATES TO CANCER RESEARCH, RESEARCHERS HAVE SUCCESSFULLY ATTRACTED SIGNIFICANT ADDITIONAL EXTERNAL FUNDING TO FURTHER THEIR RESEARCH, AVERAGING $14 FOR EVERY $1 INITIAL AWARD.SIGNIFICANT 2024 EXTERNAL FUNDING INCLUDED:BRAIN CANCERMILAN G. CHHEDA, MD RECEIVED A TEAM SCIENCE AWARD IN THE AMOUNT OF $800,000 IN 2020 AND 2021 FOR A PROJECT ENTITLED, "WASHINGTON UNIVERSITY GLIOBLASTOMA TEAM SCIENCE: AN INTEGRATED AND COLLABORATIVE APPROACH TO DEVELOP NEW THERAPIES FOR GLIOBLASTOMA". THE PURPOSE OF THIS PROPOSAL WAS TO DEVELOP A COLLABORATIVE TEAM TO APPLY FOR A LARGE GRANT FROM THE NATIONAL CANCER INSTITUTE (NCI), CALLED A SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE) GRANT. SPORE GRANTS BUILD ON LABORATORY RESEARCH FINDINGS, AND ALL PROJECTS HAVE A "HUMAN ENDPOINT"-- SOMETHING THAT WILL BE TESTED IN HUMANS OR USE HUMAN SAMPLES. DR. CHHEDA AND HIS TEAM OBTAINED DATA TO INITIATE A CLINICAL TRIAL USING LASER ABLATION-- USING A LASER TO REMOVE TUMORS AND OTHER LESIONS-- AND IMMUNOTHERAPY; THEY HAVE TESTED THE SAFETY OF ZIKA VIRUS IN TREATING CANCER IN NON-HUMAN PRIMATES, WITH A PATH NOW TO GO INTO HUMANS; AND THEY HAVE ALSO OBTAINED DATA THAT SUGGESTS PATIENTS TREATED BASED ON THEIR CIRCADIAN RHYTHMS SURVIVE LONGER. DR. CHHEDA AND HIS TEAM WERE ABLE TO LEVERAGE PRELIMINARY DATA GARNERED THROUGH THE SIP RDA PROJECT TO OBTAIN THE THREE R01 AWARDS, INCLUDING ONE FROM ERIK HERZOG, PHD AND JOSH RUBIN, MD, PHD IN JANUARY 2024 (R01 NS134885). $2.1M IN NATIONAL FUNDS RECEIVED IN 2024. BREAST CANCERIN 2022, SIP RDA FUNDED PROJECT FROM AIMILIA GASTOUNIOTI, PHD AIMED AT DISCOVERING NEW WAYS TO BRING MORE EFFECTIVE, PERSONALIZED BREAST CANCER RISK MODELS TO WOMEN USING ARTIFICIAL INTELLIGENCE (AI) AND MAMMOGRAMS. THE GOAL OF THE PROJECT WAS TO PILOT THE USE OF AI TOOLS IN THE ANALYSIS OF MAMMOGRAMS OVER TIME AND PROVIDE PATIENTS WITH A RISK SCORE. THE PROJECT WAS SUCCESSFUL IN DISCOVERING NEW WAYS OF IDENTIFYING DISEASE USING A WOMEN'S AVAILABLE HISTORY OF MAMMOGRAPHIC IMAGING AND USING CHANGES OVER TIME TO PREDICT DISEASE RISK. THIS PROJECT HAS ALREADY LED TO A SUSAN G. KOMEN CAREER CATALYST RESEARCH AWARD IN OCTOBER OF 2023 AND AN NCI R01 AWARD IN SEPTEMBER OF 2024 (R01 CA286120). $3.2M IN NATIONAL FUNDS RECEIVED IN 2024. HEAD AND NECK CANCERBEN MAJOR, PHD AND PAUL ZOLKIND, MD WERE AWARDED A $300,000 NEW CLINICAL TRIAL AWARD IN JANUARY 2023 ENTITLED, "EARLY PHASE I WINDOW OF OPPORTUNITY TRIAL OF PYRIMETHAMINE AS AN INHIBITOR OF NRF2 IN HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA". IN PRECLINICAL STUDIES, DR. MAJOR AND DR. ZOLKIND HAVE FOUND THAT SUPPRESSING DHFR (AN ENZYME THAT HELPS CANCER CELLS GROW) AND NRF2 (A PROTEIN THAT HELPS PROTECT CELLS FROM DAMAGE) SENSITIZES TUMORS TO RADIATION THERAPY. WHAT DR. MAJOR AND DR. ZOLKIND HAVE OBSERVED IS THAT ADMINISTERING PYRIMETHAMINE DRAMATICALLY INHIBITS THE FUNCTION OF THE DHFR ENZYME. THIS IS THE FIRST REPORT IN HUMANS THAT PYRIMETHAMINE (AN ANTI-PARASITIC MEDICATION) INHIBITS DHFR IN CANCER. IN ADDITION, IT'S BEEN WELL TOLERATED WITH MINIMAL TOXICITY. NO PATIENTS HAVE NEEDED TO STOP THE DRUG EARLY OR DELAY SURGERY AS A RESULT OF TREATMENT. IF THIS TRIAL IS SUCCESSFUL IN DEMONSTRATING A ROBUST MOLECULAR RESPONSE, THE NEXT PHASE WOULD BE TO EVALUATE THE EFFICACY OF PYRIMETHAMINE ADMINISTERED ALONGSIDE RADIATION THERAPY AS A SENSITIZING AGENT IN A PHASE II CLINICAL TRIAL. THIS HAS RESULTED IN R01 FUNDING FROM THE NCI IN DECEMBER 2024 (R01 CA290809). $1.8M IN NATIONAL FUNDS RECEIVED IN 2024. PROSTATE CANCERSIP RDA FUNDING SUPPORTED HANWEN ZHANG, PHD IN HIS PROJECT TO CREATE A NEW PROTEIN BLOCKER (KNOWN AS A PSMA INHIBITOR) IN THE FORM OF A RADIOTRACER TO HELP DIAGNOSE AND TREAT METASTATIC PROSTATE CANCER. RADIOTRACERS ARE COMPOUNDS THAT CAN ATTACH TO PROSTATE CANCER CELLS TO MAKE THEM 1) EASIER TO SEE VIA PET IMAGING DURING DIAGNOSIS OR TREATMENT FOLLOW-UP, AND 2) MORE SUSCEPTIBLE TO ABLATE CANCER CELLS WITH MINIMUM DAMAGE ON ADJACENT ORGANS. PHYSICIANS HAVE DEMONSTRATED A NEED FOR A MORE EFFECTIVE METHOD TO CLEARLY IDENTIFY THE EXACT LOCATION AND INTENSITY OF THE PROSTATE CANCER CELLS. DR. ZHANG'S PROJECT WILL ALLOW THE PHYSICIAN TREAT WHAT THEY SEE IN PROSTATE CANCER PATIENTS. DR. ZHANG AND HIS TEAM HAVE SHOWN THAT THE COMPOUNDS THEY ARE UTILIZING FOR THIS PURPOSE (227TH-LUMI-PSMAUREA AND 89ZR-LUMI-PSMAUREA) WORK WELL IN ANIMAL MODELS AND THEIR RESULTS WILL BE PUBLISHED THIS YEAR. THE PLAN THIS YEAR IS TO TEST WHETHER THESE COMPOUNDS ARE SAFE TO USE IN HEALTHY MICE, AT WHICH POINT THEY WILL APPLY FOR FDA APPROVAL TO MOVE TOWARDS IN-HUMAN PROSTATE CANCER TRIALS WITHIN THE NEXT TWO YEARS. THIS PROJECT HAS ALREADY LED TO AN NCI R01 AWARD IN SEPTEMBER OF 2024 TO EXPAND THIS WORK INTO THE FIELD OF NEUROBLASTOMA (R01 CA285959), A VERY COMMON FORM OF PEDIATRIC CANCER THAT IS DIFFICULT TO TREAT. $3.0M IN NATIONAL FUNDS RECEIVED IN 2024. 6577937 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 22 0 1 11 1 0 0 0 0 0 0 0 0 0 0 0 0 X 29 29 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X X ANGIE PINON 3147871990 9288 DIELMAN INDUSTRIAL DRIVE ST LOUIS MO 63132 WILLIAM TIMMONS PRESIDENT 2.00 X X 0 0 0 DAVID MOONS VICE PRESIDENT 2.00 X X 0 0 0 DAVID YONCE SECRETARY 2.00 X X 0 0 0 RENEE VAN HORN TREASURER 2.00 X X 0 0 0 ED ALIZADEH DIRECTOR 1.00 X 0 0 0 BRIAN ASHWORTH DIRECTOR (THRU 12/24) 1.00 X 0 0 0 JOE BERGER DIRECTOR 1.00 X 0 0 0 CHRISTIAN BUGYIS DIRECTOR 1.00 X 0 0 0 EMILY CALLAHAN DIRECTOR (THRU 12/24) 1.00 X 0 0 0 RYAN FIELDS DIRECTOR 1.00 X 0 0 0 BART FRENCH DIRECTOR 1.00 X 0 0 0 DAIN GIESIE DIRECTOR 1.00 X 0 0 0 JUDY GLIK DIRECTOR 1.00 X 0 0 0 TERI GRIEGE DIRECTOR (THRU 12/24) 1.00 X 0 0 0 KYLE GRIEGE DIRECTOR 1.00 X 0 0 0 DEBBIE HANKIN DIRECTOR 1.00 X 0 0 0 DENA LADD DIRECTOR 1.00 X 0 0 0 BILL LINDE DIRECTOR 1.00 X 0 0 0 DOUG MANGERS DIRECTOR 1.00 X 0 0 0 MARK MANNING DIRECTOR 1.00 X 0 0 0 JEAN MCDONALD DIRECTOR 1.00 X 0 0 0 MELISSA MERLIN DIRECTOR 1.00 X 0 0 0 RICK MOECKEL DIRECTOR 1.00 X 0 0 0 NICK OVERKAMP DIRECTOR 1.00 X 0 0 0 JAQUI ROGERS DIRECTOR 1.00 X 0 0 0 MICHAEL SCHWARTZ DIRECTOR 1.00 X 0 0 0 EMERY SKOLFIELD DIRECTOR 1.00 X 0 0 0 SHANE SPEARS DIRECTOR 1.00 X 0 0 0 NICOLE STUBBLEFIELD DIRECTOR 1.00 X 0 0 0 BRAD VERDIGETS DIRECTOR 1.00 X 0 0 0 TED WHEELER DIRECTOR 1.00 X 0 0 0 DUANE WYATT DIRECTOR 1.00 X 0 0 0 DAVID DRIER EXECUTIVE DIRECTOR 40.00 X 249976 0 15132 ASHLEY SAITTA DIRECTOR OF OPERATIONS & COMMUNITY 40.00 X 138084 0 3116 PAM MANDELKER DIRECTOR OF DEVELOPMENT 32.00 X 130038 0 10904 ELEANOR GOEDEKE DIRECTOR OF COMMUNICATIONS & MKTG 40.00 X 125386 0 17281 643484 0 46433 4 0 1 0 BIG SHARK BICYCLE CO 1155 BIG BEND SAINT LOUIS MO 63117 COURSE MANAGEMENT 130000 1 96070 8955226 166405 9051296 RIDER REGISTRATION FEE 900099 378584 378584 378584 96012 96012 70035 70035 0 0 9721 96070 96070 -86349 -86349 46680 22773 23907 23907 9463450 402491 0 9663 5204913 5204913 265107 90251 174856 688052 487775 111884 88393 13970 8824 2543 2603 99334 57962 19278 22094 72646 37776 15256 19614 2535 2535 88527 88527 173732 173732 34483 6552 27931 115902 22021 93881 49349 9376 39973 32179 32179 21162 4021 17141 21753 21753 EVENT AND DEVELOPMENT 833271 780687 52584 7716915 6577937 393997 744981 500 500 798632 918229 424608 2034851 79180 94891 18283 10919 87764 50467 37309 37297 118144 94354 1476656 3191041 118821 112466 119888 94093 238709 206559 X 728713 839748 509234 2144734 1237947 2984482 1476656 3191041 1746535 0 X 0 1 X 1 0 X 5392046 5604297 6030969 6695334 9051296 32773942 5392046 5604297 6030969 6695334 9051296 32773942 1041377 31732565 20685 40528 96012 157225 32931167 1862503 0.96360 0.96150 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 87764 50467 37297 37297 OPERATING LEASE LIABILITY 94093 94093 X 9766664 184371 118843 303214 9463450 0 9463450 8020129 184371 118843 303214 7716915 0 7716915 PART X, LINE 2: THE ORGANIZATION QUALIFIES AS A NONPROFIT ORGANIZATION AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION HAS ADDRESSED THE PROVISIONS OF ASC 740, ACCOUNTING FOR INCOME TAXES. IN THAT REGARD, THE ORGANIZATION HAS EVALUATED ITS TAX POSITIONS, EXPIRING STATUTES OF LIMITATIONS, AUDITS, PROPOSED SETTLEMENTS, CHANGES IN TAX LAW, AND NEW AUTHORITATIVE RULINGS AND BELIEVES THAT NO PROVISION FOR INCOME TAXES IS NECESSARY, AT THIS TIME, TO COVER ANY UNCERTAIN TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF COST OF GOODS SOLD AGAINST INCOME 22,773. RECLASS OF DIRECT FUNDRAISING EXPENSES AGAINST INCOME 96,070. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF COST OF GOODS SOLD AGAINST INCOME 22,773. RECLASS OF DIRECT FUNDRAISING EXPENSES AGAINST INCOME 96,070. PTC WEEKEND 105791 96070 9721 96070 105791 96070 9721 96070 96070 -86349 1 SITEMAN KIDS AT STL CHILDREN'S HOSPITAL (STL CHILDREN'S HOSP FOUND) 1001 HIGHLANDS PLAZA DR WEST 160 ST LOUIS MO 631101337 431626863 501(C)(3) 1561474 0 SUPPORT CANCER RESEARCH SITEMAN CANCER CENTER (FOUNDATION FOR BARNES JEWISH HOSP) 1001 HIGHLANDS PLAZA DR WEST 140 ST LOUIS MO 631101337 431648435 501(C)(3) 3643439 0 SUPPORT CANCER RESEARCH 2 0 PART I, LINE 2: PEDAL THE CAUSE (PTC) MAINTAINS RECORDS TO SUBSTANTIATE THE AMOUNT OF ASSISTANCE AWARDED. PTC PROVIDES FUNDING TO SITEMAN CANCER CENTER (THROUGH BARNES JEWISH HOSPITAL FOUNDATION) AND SITEMAN KIDS AT ST. LOUIS CHILDREN'S HOSPITAL (THROUGH THE ST. LOUIS CHILDREN'S HOSPITAL FOUNDATION). BOTH ORGANIZATIONS CONDUCT CANCER RESEARCH AND ARE RECOGNIZED AS TAX-EXEMPT ORGANIZATIONS UNDER INTERNAL REVENUE CODE SECTION 501(C)(3). PTC DOES NOT PRESENTLY FUND CANCER RESEARCH BY OTHER ORGANIZATIONS. X X 0 0 0 0 0 0 0 1 0 DAVID DRIER EXECUTIVE DIRECTOR 204976 0 45000 0 0 0 3000 0 12132 0 265108 0 0 0 PART I, LINE 7 THE BONUS POOL AGGREGATE AMOUNT IS A LINE ITEM IN THE ANNUAL BUDGET, APPROVED BY THE BOARD OF DIRECTORS. ALL EMPLOYEES ARE ELIGIBLE FOR A PORTION OF THE BONUS POOL, BUT NONE ARE GUARANTEED A PAYMENT, NOR IS THE AMOUNT GUARANTEED. BONUS PAYOUT IS AT THE DISCRETION OF THE EXECUTIVE COMMITTEE. THEY DETERMINE IF THE FULL POOL IS TO BE PAID, OR A PORTION THEREOF, BASED ON THE PERFORMANCE OF THE STAFF IN TERMS OF MEETING BUDGETARY EXPECTATIONS. ONCE THE EXECUTIVE COMMITTEE HAS AUTHORIZED THE BONUS AMOUNT TO BE PAID, THE BOARD PRESIDENT, IN CONSULTATION WITH THE EXECUTIVE DIRECTOR, DECIDE ON A PER STAFF PERSON AMOUNT TO BE PAID. THESE AMOUNTS ARE COMMUNICATED AS PART OF THE YEAR-END PERFORMANCE REVIEWS WITH EACH STAFF MEMBER, AND PAID BEFORE THE END OF THE CALENDAR YEAR IN A SPECIAL PAYROLL. X 8 70035 PUBLICLY TRADED EXCHANGE X EVENT MEALS 7 96070 COMPARABLE SALES X DECORATIONS 1 300 COMPARABLE SALES 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTIONS RATHER THAN THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 2 TERI GRIEGE AND KYLE GRIEGE HAVE A FAMILIAL RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS INITIALLY PREPARED BY THE OUTSIDE ACCOUNTANT. A DRAFT COPY OF THE RETURN IS PROVIDED TO MANAGEMENT FOR REVIEW. CHANGES, IF ANY, ARE DISCUSSED AND A FINAL COPY OF FORM 990 IS PRESENTED TO THE FINANCE COMMITTEE FOR REVIEW. UPON REVIEW BY THE FINANCE COMMITTEE, A COPY OF FORM 990 IS MADE AVAILABLE TO THE BOARD OF DIRECTORS FOR APPROVAL PRIOR TO FILING WITH IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO ALL DIRECTORS AND OFFICERS OF PEDAL THE CAUSE, AND ANY OTHER PERSON WHO IS IN A POSITION TO EXERCISE SUBSTANTIAL INFLUENCE OVER THE DECISIONS AND AFFAIRS OF THE CORPORATION. EACH COVERED PERSON WILL ANNUALLY SIGN A STATEMENT THAT AFFIRMS SUCH PERSON 1) HAS RECEIVED A COPY OF THE POLICY; 2) HAS READ AND UNDERSTANDS THE POLICY; 3) HAS AGREED TO COMPLY WITH THE POLICY; AND 4) UNDERSTANDS THAT THE CORPORATION IS EXEMPT FROM FEDERAL INCOME TAX AND TO MAINTAIN ITS FEDERAL TAX EXEMPTION THE CORPORATION MUST ENGAGE PRIMARILY IN ACTIVITIES THAT ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES. TO ENSURE THAT THE CORPORATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT PURPOSES AND THAT IT DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE ITS STATUS AS AN ORGANIZATION EXEMPT FROM FEDERAL INCOME TAX, THE BOARD WILL CONDUCT PERIODIC REVIEWS. THE PERIODIC REVIEWS WILL, AT A MINIMUM, INCLUDE THE FOLLOWING SUBJECTS: 1) WHETHER THE CORPORATION'S COMPENSATION ARRANGEMENTS ARE REASONABLE, BASED ON COMPETENT SURVEY INFORMATION, AND ARE THE RESULT OF ARM'S- LENGTH BARGAINING; 2) WHETHER TRANSACTION AND ARRANGEMENTS WITH OTHER ENTITIES AND INDIVIDUALS CONFORM TO THE CORPORATION'S POLICIES, ARE PROPERLY RECORDED, REFLECT REASONABLE PAYMENTS FOR GOODS AND SERVICES, FURTHER THE CORPORATION'S TAX-EXEMPT PURPOSES AND DO NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT, OR IN AN EXCESS BENEFIT TRANSACTION. WHEN CONDUCTING REVIEWS, THE BOARD SHOULD RELY ON APPROPRIATE OUTSIDE EXPERTS (ATTORNEYS, APPRAISERS, OR COMPENSATION OR OTHER CONSULTANTS). FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION OF THE EXECUTIVE DIRECTOR IS APPROVED BY THE EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION ADDRESSES REQUESTS TO VIEW GOVERNING DOCUMENTS, THE CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ON A CASE BY CASE BASIS.